Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (77946)	8/20/2025 8:03:24 PM
From: E_K_S	Read Replies (2) \| Respond to of 78507

A few Buys this week: Added IRT I see Grommit has that added LEG looking for their turnaround and almost done w/ their big manufacturing consolidation A new Health Care REIT GMRE started position moving some proceeds from PLYM sales Sold a few PAHC for excellent gains moved proceeds into ELAN a similar animal health/nutrient company More Buys in COLD in mutiple accounts. Selling at a multi year low could this be taken private? A few Sells Took some quick profits on some high cost shares of NXRT; too much debt small sell in ADM sold some high cost shares of IBIT for small gain Sold some D used proceeds to Buy COLD (in IRA account) booked gains in a small sell of OHI sold some B a gold stock held 6.5% and still achieved a 12.5% CAGR peeled off a few high cost WPC as this is oversize and a good gainer peeled off a few high cost KTB after a good run on earnings Sold all my high cost SCHD for a small gain; parked the proceeds in the Treasury Fund and ready to deploy back into SCHD on a 5%-10% market sell off; still have 50% of lower cost shares I bought during the April correction. A good long term hold if you can establish a good price. -------------------------------------------------------------------------------- Been looking at the REIT Health Care sector and have done really well from my 2023 Buys but sold alot of those Buys booking 30% CAGR. The metrics for Global Medical REIT Inc (GMRE) - Prce/FFO 8.37x; but expects Little to No Growth Here's an overview of Global Medical REIT Inc. (GMRE)'s value proposition, financial estimates, and debt profile: GMRE's Value Proposition Global Medical REIT (GMRE) is a real estate investment trust (REIT) focused on acquiring and managing licensed, state-of-the-art, purpose-built healthcare facilities. Its value proposition is built on several key aspects: Focus on Healthcare Real Estate: GMRE specializes in a sector benefiting from favorable demographic trends, particularly an aging population and the shift in healthcare delivery to local, specialized facilities (e.g., medical office buildings, inpatient rehabilitation facilities). Net-Lease Model: The majority of GMRE's revenue comes from triple-net lease agreements, where tenants are responsible for most property-related expenses. This provides a stable and predictable income stream. Dividend Income: As a REIT, GMRE is required to distribute at least 90% of its taxable income to shareholders, making it an attractive option for income-focused investors. It aims to provide reliable and potentially increasing dividends. Growth through Acquisitions: GMRE's strategy involves acquiring high-quality healthcare properties in strong markets with long-term leases and financially sound tenants. This disciplined acquisition strategy aims to drive rent, occupancy, and earnings growth. Diversified Portfolio: The company seeks to diversify its portfolio by geography, tenant type, and property type to mitigate risk. Experienced Management: GMRE highlights its experienced management team as a key strength. Price/FFO and 2026 Estimates FFO Estimates for 2026: Analysts generally expect GMRE's FFO for the fiscal year ending December 2026 to be around $0.82 per share. Some estimates range from $0.80 to $0.84. Current Debt Profile As of June 30, 2025, GMRE's debt profile includes: Total Debt Outstanding: Approximately $713.0 million, including outstanding borrowings on its credit facility and notes payable (net of unamortized debt issuance costs). Leverage: The company's leverage was 47.2% as of June 30, 2025. Weighted Average Interest Rate: As of June 30, 2025, the weighted average interest rate on its total debt was 4.09%. Weighted Average Remaining Term: The weighted average remaining term of its debt was 1.6 years as of June 30, 2025. Debt Maturity: A $350 million Term Loan A component of its credit facility matures in May 2026. GMRE is in active discussions with lenders to refinance this obligation and extend the maturity date of its Revolver. They anticipate completing this refinancing during the fourth quarter of 2025. A Term Loan B of its credit facility matures in February 2028. The Revolver component of its credit facility matures in August 2026, with two six-month extension options. One loan, the Rosedale Loan, has an annual interest rate of 3.85% and matures on July 31, 2025. Another loan, the Toledo Loan, has an annual interest rate of 5.0% and matures on July 30, 2033. ------------------------------------------------------------------------------------------------